Peter Wijngaard
Net worth: 12 256 $ as of 2024-04-29
Profile
Peter L.
J.
Wijngaard served as Chairman at Aurinia Pharmaceuticals, Inc. and as Director at Ciclofilin Pharmaceuticals, Inc. He was also an Independent Non-Executive Director at Isotechnika Pharma, Inc. and held a Director-Global Alliance position at Hoffmann-La Roche, Inc. Additionally, he was the VP-Innovation Leader Research & Development at The Medicines Company (Schweiz) GmbH.
Wijngaard earned a doctorate degree from the University of Utrecht in 1992.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-11-26 | 9,501 ( 0.17% ) | 12 256 $ | 2024-04-29 |
Former positions of Peter Wijngaard
Companies | Position | End |
---|---|---|
HEPION PHARMACEUTICALS, INC. | Director/Board Member | 2023-12-03 |
The Medicines Company (Schweiz) GmbH | Corporate Officer/Principal | 2019-12-31 |
Ciclofilin Pharmaceuticals, Inc.
Ciclofilin Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers antiviral drug development, liver disease, viral co-infection, cyclophilin inhibition, macrocycle chemistry and protein folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA. | Director/Board Member | 2016-05-31 |
Isotechnika Pharma, Inc.
Isotechnika Pharma, Inc. Pharmaceuticals: MajorHealth Technology Isotechnika Pharma, Inc. is a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules. The company was founded by Robert T. Foster founded on June 16, 1993 and is headquartered in Edmonton, Canada. | Director/Board Member | 2013-10-22 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Director/Board Member | - |
Training of Peter Wijngaard
University of Utrecht | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
HEPION PHARMACEUTICALS, INC. | Health Technology |
AURINIA PHARMACEUTICALS INC. | Health Technology |
Private companies | 4 |
---|---|
Ciclofilin Pharmaceuticals, Inc.
Ciclofilin Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers antiviral drug development, liver disease, viral co-infection, cyclophilin inhibition, macrocycle chemistry and protein folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Isotechnika Pharma, Inc.
Isotechnika Pharma, Inc. Pharmaceuticals: MajorHealth Technology Isotechnika Pharma, Inc. is a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules. The company was founded by Robert T. Foster founded on June 16, 1993 and is headquartered in Edmonton, Canada. | Health Technology |
The Medicines Company (Schweiz) GmbH |
- Stock Market
- Insiders
- Peter Wijngaard